NANOTHER
Integration of Novel Nanoparticle based Technology for Therapeutics and Diagnosis of different types of Cancer
| Coordinatore | FUNDACION GAIKER
Organization address
address: Parque Tecnologico de Zamudio, Edificio 202 contact info |
| Nazionalità Coordinatore | Spain [ES] |
| Sito del progetto | http://www.nanother.eu/ |
| Totale costo | 11˙556˙307 € |
| EC contributo | 8˙408˙483 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2007-LARGE-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-09-01 - 2012-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FUNDACION GAIKER
Organization address
address: Parque Tecnologico de Zamudio, Edificio 202 contact info |
ES (ZAMUDIO) | coordinator | 1˙187˙724.90 |
| 2 |
Institut polytechnique de Bordeaux
Organization address
address: AV DU DOCTEUR ALBERT SCHWEITZER 1 contact info |
FR (TALENCE) | participant | 952˙208.75 |
| 3 |
CONSORZIO INTERUNIVERSITARIO NAZIONALE PER LA SCIENZA E TECNOLOGIA DEI MATERIALI
Organization address
address: Via Giusti 9 contact info |
IT (FIRENZE) | participant | 951˙284.00 |
| 4 |
TEL AVIV UNIVERSITY
Organization address
address: RAMAT AVIV contact info |
IL (TEL AVIV) | participant | 810˙170.25 |
| 5 |
COLOROBBIA ITALIA SPA
Organization address
address: VIA PIETRAMARINA 53 contact info |
IT (SOVIGLIANA VINCI) | participant | 505˙700.00 |
| 6 |
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
Organization address
address: Rue de la Loi 200 contact info |
BE (BRUSSELS) | participant | 405˙051.00 |
| 7 |
ACONDICIONAMIENTO TARRASENSE ASSOCIACION
Organization address
address: CARRER DE LA INNOVACIO 2 contact info |
ES (TERRASSA) | participant | 403˙388.00 |
| 8 |
ASOCIACION CENTRO DE TECNOLOGIAS DE INTERACCION VISUAL Y COMUNICACIONES-VICOMTECH
Organization address
address: PASEO MIKELETEGI PARQUE TECNOLOGICO DE MIRAMON 57 contact info |
ES (DONOSTIA / SAN SEBASTIAN) | participant | 347˙662.50 |
| 9 |
ALMA CONSULTING GROUP SAS
Organization address
address: Domaine des Bois d'Houlbec contact info |
FR (HOULBEC COCHEREL) | participant | 343˙880.00 |
| 10 |
TECHNOLOGIKO EKPAIDEFTIKO IDRYMA ATHINAS
Organization address
address: AGIOU SPYRIDONOS 28 KAI MILOU 1 contact info |
EL (AIGALEO) | participant | 342˙840.00 |
| 11 |
"PHARMAMAR, S.A.U."
Organization address
address: "Avda. de los Reyes , Poligono Industrial La Mina 1" contact info |
ES (COLMENAR VIEJO (MADRID)) | participant | 332˙380.50 |
| 12 |
UNIVERSITE VICTOR SEGALEN BORDEAUX II
Organization address
address: RUE LEO SAIGNAT 146 contact info |
FR (BORDEAUX CEDEX) | participant | 326˙016.00 |
| 13 |
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
Organization address
address: PARQUE TECNOLOGICO EDIFICIO 801 A contact info |
ES (DERIO VIZCAYA) | participant | 288˙315.00 |
| 14 |
NuovoProbe Ltd
Organization address
address: Wigmore Street 128 contact info |
UK (London) | participant | 278˙692.00 |
| 15 |
HAMELN RDS AS
Organization address
address: HORNA 36 contact info |
SK (MODRA) | participant | 275˙734.44 |
| 16 |
AHAVA DEAD SEA LABORATORIES LTD
Organization address
address: Hatsoref street 5 contact info |
IL (HOLON) | participant | 256˙492.50 |
| 17 |
DOMINION PHARMAKINE S.L.
Organization address
address: BIZKAIA TECHNOLOGY PARK Building 801A contact info |
ES (DERIO) | participant | 158˙295.05 |
| 18 |
FEYECON DEVELOPMENT & IMPLEMENTATION BV
Organization address
address: RIJNKADE 17A contact info |
NL (WEESP) | participant | 121˙800.00 |
| 19 |
ARGUS CHEMICAL SRL
Organization address
address: VIA DEL MOLIN NUOVO 10 contact info |
IT (59024) | participant | 120˙848.15 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The breakthrough objective of NANOTHER is to develop & characterise a novel nanoparticle system that will be used as a therapeutic agent or diagnosis tool for breast cancer, colorectal cancer & bone metastasis. Theranostics, the development of nanoparticles with both functionalities, will also be carried out using the hyperthermic effect to kill tumour cells or to release the selected drug . The nanoparticles used in NANOTHER will be selected based on previous studies. Therefore, only polymeric micelles core-shell nanoparticles and magnetic nanoparticles will be included in the study. The nanoparticles will be functionalised by attaching targeting molecules, depending on the type of cancer to be treated or diagnosed. Labels for diagnosis will include fluorescent or contrast phase probes, which will later be imaged and analysed with the appropriate equipment optimised during the project. Therapeutic agents will be loaded on to the nanoparticle, including drugs like doxorubicin, and new marine pharmacological compounds already in clinical trials. One of the most innovative aspects of this proposal is the use of siRNA as the therapeutic agent. The use of magnetic nanoparticles as a theranostic mechanism is also an innovative aspect of the proposal, as these nanoparticles can be activated to kill tumour cells detected depending on a positive or negative diagnostic. The project has been structured in seven different sub-projects including aspects like toxicology, biocompatibility of the nanodevices, and also efficacy and biodistribution of the system. In vitro (cellular models) & in vivo assays (small animals; mice) will be used for the study of diagnosis & therapy. The latter will be kept to the minimum necessary to study the efficiency & biodistribution and always taking into account the three Rs & national / EU norms. The NANOTHER consortium includes 18 top-level partners from 8 EU countries as the critical mass required to achieve ambitious project objectives.'
Introduzione (Teaser)
Cancer is the leading cause of death in Europe, surpassed only by cardiovascular disease. Scientists developed novel technology that could yield a one-step diagnosis and treatment for cancer.